Key clinical point: Adding pembrolizumab to chemotherapy may improve outcomes in untreated extensive-stage small cell lung cancer.
Major finding: The median progression-free survival was 4.5 months with pembrolizumab and 4.3 months with placebo.
Study details: A randomized phase 3 trial of 453 patients with untreated extensive-stage small cell lung cancer.
Disclosures: Merck Sharp & Dohme supported the study. Dr. Rudin disclosed institutional research funding from Merck and a consulting or advisory role for other companies.
Rudin CM et al. ASCO 2020. Abstract 9001.